Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease
November 29 2023 - 6:30AM
Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to
unraveling the mysteries of the brain
to treat neuroscience diseases, announced it will
host a tavapadon investor webcast on Monday, December 11, from
10:00 to 11:30 a.m. ET.
Cerevel will lead an in-depth discussion of
tavapadon, its D1/D5 partial agonist currently in Phase 3
development for the treatment of Parkinson’s disease. The event
will include remarks and insights from Hubert Fernandez, M.D.,
Director, Center for Neurological Restoration at Cleveland Clinic
and recognized key opinion leader in Parkinson’s disease.
“I am excited about the potential of tavapadon,
the first and only selective D1/D5 partial agonist being studied
for Parkinson’s disease,” said Dr. Raymond Sanchez, Cerevel’s chief
medical officer. “We know there is a significant need for a novel
treatment option that provides sustained motor control without
non-motor side effect tradeoffs and look forward to discussing our
hope for delivering tavapadon to people living with
Parkinson’s."
Tavapadon is currently being studied for
Parkinson’s disease in the Phase 3 TEMPO program. The TEMPO-3
trial, which is expected to read out in the first half of 2024, is
evaluating tavapadon as an adjunctive treatment to levodopa. The
TEMPO-1 and TEMPO-2 trials, which will read out in the second half
of 2024, are evaluating tavapadon as a monotherapy treatment.
This investor event will provide a detailed look
at tavapadon’s differentiating features, previously published
clinical data, the design of the TEMPO program, and the potential
opportunity of tavapadon to meet unmet patient needs within the
Parkinson’s disease treatment paradigm. The presentations will be
followed by time for questions.
The live webcast, along with supporting slides,
will be accessible on the investors section of Cerevel’s website
here. Following the live webcast, an archived version of the event
will be available on the website.
About Cerevel
TherapeuticsCerevel Therapeutics is dedicated to
unraveling the mysteries of the brain to treat neuroscience
diseases. The company is tackling diseases by combining its deep
expertise in neurocircuitry with a focus on targeted receptor
subtype selectivity and a differentiated approach to pharmacology.
Cerevel Therapeutics has a diversified pipeline comprised of five
clinical-stage investigational therapies and several preclinical
compounds with the potential to treat a range of neuroscience
diseases, including schizophrenia, Alzheimer’s disease psychosis,
epilepsy, panic disorder, and Parkinson’s disease. Headquartered in
Cambridge, Mass., Cerevel Therapeutics is advancing its current
research and development programs while exploring new modalities
through internal research efforts, external collaborations, or
potential acquisitions. For more information, visit
www.cerevel.com.
Special Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements that are based on management’s beliefs and assumptions
and on information currently available to management. In some
cases, you can identify forward-looking statements by the following
words: “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. Although we believe that we
have a reasonable basis for each forward-looking statement
contained in this press release, we caution you that these
statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain. Forward-looking statements in this
press release include, but are not limited to, statements about our
upcoming investor webcast; the potential attributes and benefits of
our product candidates; the format, timing and objectives of our
product development activities and clinical trials; the ability to
compete with other companies currently marketing or engaged in the
development of treatments for relevant indications; the size and
growth potential of the markets for product candidates and ability
to serve those markets; and the rate and degree of market
acceptance of product candidates, if approved. We cannot assure you
that the forward-looking statements in this press release will
prove to be accurate. Furthermore, if the forward-looking
statements prove to be inaccurate, the inaccuracy may be material.
Actual performance and results may differ materially from those
projected or suggested in the forward-looking statements due to
various risks and uncertainties, including, among others: clinical
trial results may not be favorable; uncertainties inherent in the
product development process (including with respect to the timing
of results and whether such results will be predictive of future
results); the impact of COVID-19 and the post-COVID landscape on
the timing, progress and results of ongoing or planned clinical
trials; our ability to recruit and enroll suitable patients in our
clinical trials, including the effectiveness of mitigation
measures; whether and when, if at all, our product candidates will
receive approval from the FDA or other regulatory authorities, and
for which, if any, indications; competition from other
biotechnology companies; uncertainties regarding intellectual
property protection; and other risks identified in our SEC filings,
including those under the heading “Risk Factors” in our Quarterly
Report on Form 10-Q filed with the SEC on November 1, 2023 and our
subsequent SEC filings. In light of the significant uncertainties
in these forward-looking statements, you should not regard these
statements as a representation or warranty by us or any other
person that we will achieve our objectives and plans in any
specified time frame, or at all. The forward-looking statements in
this press release represent our views as of the date of this press
release. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update
these forward-looking statements at some point in the future, we
have no current intention of doing so except to the extent required
by applicable law. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Media Contact:Anna RobinsonCerevel Therapeutics
anna.robinson@cerevel.com
Investor Contact:Matthew CalistriCerevel
Therapeuticsmatthew.calistri@cerevel.com
Cerevel Therapeutics (NASDAQ:CERE)
Historical Stock Chart
From Apr 2024 to May 2024
Cerevel Therapeutics (NASDAQ:CERE)
Historical Stock Chart
From May 2023 to May 2024